Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

[1]  E. Beswick,et al.  Inhibition of MK2 suppresses IL‐1β, IL‐6, and TNF‐α‐dependent colorectal cancer growth , 2018, International journal of cancer.

[2]  Maryam Rashidi,et al.  RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL , 2015, Nature Communications.

[3]  Jiwang Zhang,et al.  Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML , 2014, The Journal of experimental medicine.

[4]  Yigong Shi,et al.  Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. , 2014, Journal of medicinal chemistry.

[5]  James M. Bogenberger,et al.  Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. , 2014, Journal of the National Cancer Institute.

[6]  L. Munoz,et al.  Mitogen-Activated Protein Kinase–Activated Protein Kinase 2 in Neuroinflammation, Heat Shock Protein 27 Phosphorylation, and Cell Cycle: Role and Targeting , 2014, Molecular Pharmacology.

[7]  Lars Kjeldsen,et al.  Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Toru Okamoto,et al.  The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. , 2013, Immunity.

[9]  J. Silke,et al.  Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. , 2013, Cold Spring Harbor perspectives in biology.

[10]  Dario R Alessi,et al.  Kinase drug discovery--what's next in the field? , 2013, ACS chemical biology.

[11]  Q. Xue,et al.  LY2228820 Dimesylate, a Selective Inhibitor of p38 Mitogen-activated Protein Kinase, Reduces Angiogenic Endothelial Cord Formation in Vitro and in Vivo* , 2013, The Journal of Biological Chemistry.

[12]  H. Kantarjian,et al.  Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS , 2012, Cancer.

[13]  S. Gygi,et al.  A novel role for RIP1 kinase in mediating TNFα production , 2012, Cell Death and Disease.

[14]  Andrew Kasarskis,et al.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia , 2012, Nature.

[15]  S. Fulda,et al.  Targeting IAP proteins for therapeutic intervention in cancer , 2012, Nature Reviews Drug Discovery.

[16]  A. Burnett.  New induction and postinduction strategies in acute myeloid leukemia , 2012, Current opinion in hematology.

[17]  Holly Anderton,et al.  Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. , 2012, Immunity.

[18]  Taebo Sim,et al.  Discovery of potent and selective covalent inhibitors of JNK. , 2012, Chemistry & biology.

[19]  Xiaodong Wang,et al.  Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase , 2012, Cell.

[20]  R. Campbell,et al.  Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity , 2011, Molecular Cancer Therapeutics.

[21]  G. Häcker,et al.  cIAPs Block Ripoptosome Formation, a RIP1/Caspase-8 Containing Intracellular Cell Death Complex Differentially Regulated by cFLIP Isoforms , 2011, Molecular cell.

[22]  T. Tenev,et al.  The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. , 2011, Molecular cell.

[23]  Saptarsi M. Haldar,et al.  S-Nitrosylation at the interface of autophagy and disease. , 2011, Molecular cell.

[24]  L. Bullinger,et al.  Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups , 2011, Leukemia.

[25]  David R. Anderson,et al.  A Benzothiophene Inhibitor of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Inhibits Tumor Necrosis Factor α Production and Has Oral Anti-Inflammatory Efficacy in Acute and Chronic Models of Inflammation , 2010, Journal of Pharmacology and Experimental Therapeutics.

[26]  Tao Wang,et al.  Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-α , 2009, Cell.

[27]  F. Chan,et al.  Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation , 2009, Cell.

[28]  Michael Kracht,et al.  Targeting innate immunity protein kinase signalling in inflammation , 2009, Nature Reviews Drug Discovery.

[29]  J. Downing,et al.  Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.

[30]  P. Cohen.  Targeting protein kinases for the development of anti-inflammatory drugs. , 2009, Current opinion in cell biology.

[31]  J. Wilson,et al.  Identification of the murine firefly luciferase-specific CD8 T-cell epitopes , 2009, Gene Therapy.

[32]  M. Genovese.  Inhibition of p38: has the fat lady sung? , 2009, Arthritis and rheumatism.

[33]  R. Flavell,et al.  Induction of Hepatitis by JNK-Mediated Expression of TNF-α , 2009, Cell.

[34]  A. Doherty,et al.  The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. , 2008, Bioorganic & medicinal chemistry letters.

[35]  J. Keats,et al.  Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling , 2008, Nature Immunology.

[36]  T. Mak,et al.  Activation of noncanonical NF-κB requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2, TRAF3 and the kinase NIK , 2008, Nature Immunology.

[37]  M. Bertrand,et al.  cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. , 2008, Molecular cell.

[38]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[39]  W. Sellers,et al.  A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. , 2007, Cancer research.

[40]  David L. Vaux,et al.  IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.

[41]  Vishva M. Dixit,et al.  IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.

[42]  J. Minna,et al.  Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. , 2007, Cancer cell.

[43]  M. Gaestel,et al.  The Mitogen-Activated Protein Kinase (MAPK)-Activated Protein Kinases MK2 and MK3 Cooperate in Stimulation of Tumor Necrosis Factor Biosynthesis and Stabilization of p38 MAPK , 2006, Molecular and Cellular Biology.

[44]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[45]  P. Cohen,et al.  Feedback control of the protein kinase TAK1 by SAPK2a/p38α , 2003, The EMBO journal.

[46]  J. Tschopp,et al.  NF-κB Signals Induce the Expression of c-FLIP , 2001, Molecular and Cellular Biology.

[47]  G. Kollias,et al.  TNF-α Induction by LPS Is Regulated Posttranscriptionally via a Tpl2/ERK-Dependent Pathway , 2000, Cell.

[48]  J C Reed,et al.  IAPs block apoptotic events induced by caspase‐8 and cytochrome c by direct inhibition of distinct caspases , 1998, The EMBO journal.

[49]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[50]  C V Jongeneel,et al.  Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages , 1990, The Journal of experimental medicine.

[51]  D. Vaux,et al.  PHAGOCYTES , GRANULOCYTES , AND MYELOPOIESIS cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK 1-and RIPK 3-dependent manner , 2014 .

[52]  J. Silke,et al.  IAP family of cell death and signaling regulators. , 2014, Methods in enzymology.

[53]  Julian Blagg,et al.  A public-private partnership to unlock the untargeted kinome. , 2013, Nature chemical biology.

[54]  M. Patnaik,et al.  Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.

[55]  Vishva M Dixit,et al.  IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. , 2007, Cell.

[56]  G. Kollias,et al.  TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. , 2000, Cell.

[57]  M. Gaestel,et al.  MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. , 1999, Nature cell biology.

[58]  M. Gaestel,et al.  Kotlyarov, A. et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell Biol. 1, 94-97 , 1999 .